Giulia Cursano

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy.

Journal: Breast cancer research : BCR

Published: January 19, 2025

Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.

Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.

Journal: Molecular diagnosis & therapy

Published: January 08, 2025

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.

Journal: Pathologica

Published: January 04, 2025

Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact.

Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 27, 2024

Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer.

Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer.

Journal: Computational and structural biotechnology journal

Published: October 07, 2024

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Journal: The Lancet. Oncology

Published: September 23, 2024

Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.

Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.

Journal: Critical reviews in oncology/hematology

Published: April 23, 2024

The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.

The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy.

Journal: International journal of molecular sciences

Published: April 15, 2024

Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.

Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.

Journal: Cancers

Published: April 10, 2024

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.

Journal: Pharmacogenomics

Published: March 05, 2024

Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.

Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.

Journal: Pathologica

Published: November 02, 2023

ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.

ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.

Journal: Cancer treatment reviews

Published: August 19, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026